Showing 4861-4870 of 9576 results for "".
- ADORING 3: Tapinarof Cream Maintains AD Clearance for 80 Days Post-Treatmenthttps://practicaldermatology.com/news/adoring-3-tapinarof-cream-maintains-ad-clearance-80-days-post-treatment/2468482/Results from the ADORING 3 long-term extension study showed that VTAMA® (tapinarof) cream, 1% achieved complete skin clearance in atopic dermatitis (AD) patients as young as two years old, maintaining clear or nearly clear skin for an average of 80 days post-treatment. The 48-week study, p
- LEO Pharma Announced CHE Awareness Campaignhttps://practicaldermatology.com/news/leo-pharma-announced-che-awareness-campaign/2468442/LEO Pharma Inc. has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical and emotional impact of chronic hand eczema (CHE)—a debilitating skin condition for which there are currently no FDA approved treatments. <
- READY-4: Sustained and Safety Efficacy of RelabotulinumtoxinAhttps://practicaldermatology.com/news/ready-4-sustained-and-safety-efficacy-relabotulinumtoxina/2468443/New results from the phase III READY-4 trial presented at the 2024 ASDS Annual Meeting demonstrate the long-term safety and sustained efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) for the treatment of moderate-to-severe frown lines and crow’s feet. The multicenter, open-label REA
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://practicaldermatology.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2468433/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. The goal of the rebrand is
- LEO Pharma Says Anzupgo Launch in Germany Is 'First of Many'https://practicaldermatology.com/news/leo-pharma-says-anzupgo-launch-germany-first-many/2468408/Delgocitinib cream was launched for the first time worldwide in Germany, under the name Anzupgo®, LEO Pharma said in a press release. The drug was approved in September by the European Commission (EC) for the treatment of adult patients with moderate-to-severe chronic hand eczema (CHE), fo
- European Decentralized Regulatory Procedure Completed for Efinaconazolehttps://practicaldermatology.com/news/european-decentralized-regulatory-procedure-completed-efinaconazole/2468407/Almirall, S.A. announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of onychomycosis, under the trade name of Jublia®. The low binding affinity of efinaconazole topical to kerat
- Analysis: Higher Infection and Acne Risks with JAK Inhibitors in ADhttps://practicaldermatology.com/news/analysis-higher-infection-and-acne-risks-jak-inhibitors-ad/2468381/Researchers for a new analysis have provided a data and analytics framework for the evaluation of the safety of immune-modulating drugs (IMDs) in treating atopic dermatitis (AD). The study authors designed the system to generate timely, high-quality evidence using sequential propensity sco
- Long-Term Mortality in Epidermal Necrolysis Influenced by In-Hospital Complicationshttps://practicaldermatology.com/news/long-term-mortality-epidermal-necrolysis-influenced-hospital-complications/2468372/Epidermal necrolysis (EN) is associated with high in-hospital and post-discharge mortality rates, with comorbidities playing a significant role in outcomes. Researchers for the recent cohort study used French Health System data to characterize mortality and sequelae associated with EN, whi
- Study Explores 'Poppers Dermatitis' From Recreational Drugshttps://practicaldermatology.com/news/study-explores-poppers-dermatitis-recreational-drugs/2468371/Exposure to the chemicals in recreational drugs known as “poppers” could cause dermatitis, George Washington University researchers said in a press release about a study published in the Journal of the Drugs and Dermatology. Poppers are often used by gay men for their euphoric eff
- New Study From Valisure Extends Previous Research on Benzoyl Peroxide Productshttps://practicaldermatology.com/news/study-benzene-risks-common-benzoyl-peroxide-products/2468369/A new study conducted by Valisure has raised concern about benzene contamination in benzoyl peroxide (BPO) drug products used for acne and rosacea treatment. Among 111 tested BPO products, 34% contained benzene concentrations exceeding the FDA's conditional limit of 2 parts per million (pp